The ECI1 (Enoyl-CoA Delta Isomerase 1) antibody is a tool used to detect ECI1. a mitochondrial enzyme critical in fatty acid β-oxidation. ECI1. also known as DCI or ECH1. catalyzes the isomerization of 3-trans-enoyl-CoA to 2-trans-enoyl-CoA intermediates, facilitating the breakdown of unsaturated fatty acids. This enzyme plays a vital role in energy metabolism and is expressed ubiquitously, with high activity in tissues reliant on fatty acid oxidation, such as the liver, heart, and skeletal muscle. Dysregulation of ECI1 has been implicated in metabolic disorders, neurodegenerative diseases, and cancer, making it a subject of interest in biomedical research.
The ECI1 antibody is commonly utilized in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study protein expression, localization, and pathological alterations. Researchers employ it to investigate metabolic dysfunction, mitochondrial disorders, and disease mechanisms linked to lipid metabolism. Commercial ECI1 antibodies are typically raised in rabbits or mice against specific epitopes of the human ECI1 protein, with validation in multiple applications. Its specificity and reliability are crucial for elucidating ECI1's role in cellular homeostasis and disease, offering insights into therapeutic targeting of metabolic pathways.